BrightSpring Health Services, Inc. (BTSG)
NEUTRALFundamental
67
Kurs
$56.63
Marktkapitalisierung
$11.62B
Teil 1 · Was das Unternehmen wert ist
Übersicht
BrightSpring Health Services, Inc. operates as a home and community-based healthcare services platform in the United States. The company operates through two segments, Pharmacy Solutions and Provider Services. Its platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services; and patient-centric, highly skilled, and compassionate clinical home health care, as well as rehabilitation services, including physical, speech and occupational therapy and applied behavioral analysis. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. BrightSpring Health Services, Inc. was founded in 1974 and is headquartered in Louisville, Kentucky.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$14.37B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$366M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$395M
Gesamtes Eigenkapital
$1.88B
Gesamtverbindlichkeiten
$4.53B
Current Ratio
1.59
Zinsdeckungsgrad
2.94
Schulden/EBITDA
5.20
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$71.31
Aktueller Kurs
$56.63
Sicherheitsmarge
+20.6%
Innerer-Wert-Spanne
$56.87 - $85.75
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
36.05
ROE
10.2%
P/B-Verhältnis
5.75
P/FCF
29.26
Bruttomarge
12.4%
ROIC
8.0%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
8.0%
WACC
13.2%
ROIC − WACC
-5.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (18)
- EPS shows upward trend
- Price CAGR 86.00%
- ROIC 8.0%
- P/FCF 29.26
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 19.0%
- Revenue Growth 5Y 18.3%
- Analyst Consensus 96% Buy
- Earnings Surprise avg 17.2%
- PEG Ratio 0.68
- Earnings Quality (OCF/NI) 1.38
- Net Margin Trend 2.5% vs 0.6%
- Piotroski F-Score 7/9
Nicht bestanden (8)
- Gross Margin 12.4%
- P/B Ratio 5.75
- Operating Margin 3.1%
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 9.2%
Nicht verfügbar (1)
- Dividend Payout NaN%
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Jon B. Rousseau | Chairman, President & CEO | 51 |
| Ms. Jennifer A. Phipps | CFO, Executive VP & Corporate Secretary | 44 |
| Ms. Lisa Nalley | Chief of Staff & Senior VP of Human Resources | 52 |
| Ms. Jennifer Yowler | Senior VP of Sales & Account Management - PharMerica | 48 |
| Mr. Scott Greenwell Pharm.D. | Executive VP & President of PharMerica | - |
| Mr. Charles H. Wardrip | Chief Information Officer | - |
Prüfungsrisiko
7
Vorstandsrisiko
9
Vergütungsrisiko
8
Aktionärsrechterisiko
8
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for BTSG, sourced from Markets Gazette.
- 2/27/2026NEUTRALBrightSpring (BTSG) Earnings Call Transcript
Markets Gazette reports that BrightSpring Health Services, Inc. (BTSG) held its earnings call on February 27, 2026. However, the detailed content of the transcript is not yet publicly available. Without access to specific financial data, future guidance, or management commentary, investors lack concrete elements to assess the company's performance or outlook. The absence of information prevents a clear directional analysis, leaving the stock in a holding pattern. The market will remain in suspense until the details are published, which could then trigger significant movements once key data points are released.
via Markets Gazette